Watch ETON. Know when insiders buy.
One email the day a filing lands. Free.
ETON
Eton Pharmaceuticals, Inc.
49.30
−0.89 −1.77%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
45
WATCH · insiders 25, shorts 65
Insiders, 90 days
−$10.9M
net selling · 0 buys, 9 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.4BP/E 126.4DIV YIELD —FCF YIELD 1.05%REV TTM $105.6M +81.5%NET INCOME $12.7MNET DEBT $3.1M52W 14.35 – 64.43NEXT EARNINGS Nov 12SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $37.6M | +98.6% | 67.6% | $12.8M | $11.6M | — | 0.35 | $7.3M | −$5K | $7.3M | Aug 13 |
| Q1 2026 · Mar 31 | $24.3M | +40.4% | 60.7% | $2.4M | $1.6M | — | 0.05 | $7.4M | $75K | $7.3M | May 14 |
| Q4 2025 · Dec 31derived | $21.3M | +82.7% | 61.6% | $2.5M | $1.5M | — | 0.06 | −$11.6M | $49K | −$11.6M | Mar 19 |
| Q3 2025 · Sep 30 | $22.5M | +117.5% | 35.0% | −$1.4M | −$1.9M | −407.3% | -0.07 | $12M | $284K | $11.7M | Nov 6 |
| Q2 2025 · Jun 30 | $18.9M | +108.6% | 63.0% | −$1.5M | −$2.6M | — | -0.10 | $8M | $0 | $8M | Aug 13 |
| Q1 2025 · Mar 31 | $17.3M | +116.9% | 57.1% | −$470K | −$1.6M | — | -0.06 | $2.1M | $0 | $2.1M | May 14 |
| Q4 2024 · Dec 31derived | $11.6M | +59.3% | 55.6% | $629K | −$598K | — | -0.03 | −$765K | $12K | −$777K | Mar 19 |
| Q3 2024 · Sep 30 | $10.3M | +46.9% | 61.0% | $509K | $627K | — | 0.02 | $3M | $0 | $3M | Nov 6 |
| Q2 2024 · Jun 30 | $9.1M | — | 62.0% | −$2.9M | −$3M | — | -0.12 | $1.3M | $0 | $1.3M | Aug 7 |
| Q1 2024 · Mar 31 | $8M | — | 62.9% | −$800K | −$811K | — | -0.03 | −$2.5M | $14K | −$2.5M | May 13 |
| Q4 2023 · Dec 31derived | $7.3M | — | 49.6% | −$2M | −$2.3M | — | -0.09 | $387K | $0 | $387K | Mar 19 |
| Q3 2023 · Sep 30 | $7M | — | 62.6% | −$548K | −$579K | — | -0.02 | $873K | $0 | $873K | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $80M | 53.5% | −$844K | −$4.6M | -5.8% | -0.17 | $10.5M | $333K | $10.2M | — | — |
| FY2024 · to Dec 31 | $39M | 60.0% | −$2.6M | −$3.8M | -9.8% | -0.15 | $969K | $26K | $943K | — | — |
| FY2023 · to Dec 31 | $31.6M | 66.6% | −$1.2M | −$936K | -3.0% | -0.04 | $6.8M | $0 | $6.8M | — | — |
| FY2022 · to Dec 31 | $21.3M | 67.4% | −$8.3M | −$9M | -42.4% | -0.36 | $4.8M | $38K | $4.8M | — | — |
| FY2021 · to Dec 31 | $21.8M | 87.1% | −$1.5M | −$2M | -9.0% | -0.08 | −$4.7M | $9K | −$4.7M | — | — |
| FY2020 · to Dec 31 | $39K | -1017.9% | −$27.1M | −$28M | -71717.9% | -1.33 | −$22.3M | $50K | −$22.4M | — | — |
Every number comes from Eton Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.